View of Cost-eﬀectiveness of brentuximab vedotin in treating increased risk of relapse/progression of classical hodgkin lymphoma patients post autologous stem cell transplant

Return to Article Details Cost-eﬀectiveness of brentuximab vedotin in treating increased risk of relapse/progression of classical hodgkin lymphoma patients post autologous stem cell transplant Download Download PDF